Castle Biosciences, Inc.
CSTL
$21.98
$0.843.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.62% | -1.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.62% | -1.40% | |||
| Cost of Revenue | 3.68% | 7.51% | |||
| Gross Profit | -0.06% | -3.19% | |||
| SG&A Expenses | -1.06% | -1.15% | |||
| Depreciation & Amortization | 91.02% | 1.11% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.93% | -1.57% | |||
| Operating Income | -20.26% | 1.34% | |||
| Income Before Tax | -4.79% | 5.02% | |||
| Income Tax Expenses | -128.36% | 681.53% | |||
| Earnings from Continuing Operations | 322.65% | -74.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 322.65% | -74.56% | |||
| EBIT | -20.26% | 1.34% | |||
| EBITDA | 13.90% | 3.11% | |||
| EPS Basic | 318.40% | -74.74% | |||
| Normalized Basic EPS | -12.37% | 4.26% | |||
| EPS Diluted | 292.63% | -74.19% | |||
| Normalized Diluted EPS | -13.86% | 2.68% | |||
| Average Basic Shares Outstanding | 1.03% | 0.70% | |||
| Average Diluted Shares Outstanding | 2.72% | 2.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||